Aspen Neuroscience Cofounder Dr. Andrés Bratt-Leal Receives 2023 Biocom California Life Science Catalyst Award
Dr. Andrés Bratt-Leal, co-founder and Senior Vice President of Research and Development at Aspen Neuroscience, has been honored with the prestigious 2023 Biocom California Life Science Catalyst Award. This accolade, presented by Biocom California, recognizes the most inspiring and driven young minds in the California life sciences industry who are making significant contributions to human […]
Stem Cell-Based Therapies for Lymphoma
Understanding Lymphoma and the Promise of Stem Cell Therapy Lymphoma, a type of blood cancer that affects the lymphatic system, presents a significant health challenge worldwide. It’s a complex disease with various subtypes, each requiring a unique approach to treatment. In recent years, stem cell therapy has emerged as a beacon of hope for many […]
Induced Pluripotent Stem Cells (iPSCs) for Treating Heart Failure
Overview of Heart Failure Heart failure, a condition affecting millions worldwide, is a complex clinical syndrome resulting from any structural or functional impairment of ventricular filling or ejection of blood. It’s a leading cause of hospitalization in people over the age of 65, underscoring a significant health and economic burden. Despite advancements in pharmacological and […]
BrainStorm Cell Therapeutics Announces Key FDA Meeting for ALS Treatment
BrainStorm Cell Therapeutics Inc., a prominent developer of adult stem cell therapies for neurodegenerative diseases, has announced a significant development in their pursuit of treating amyotrophic lateral sclerosis (ALS). The company has secured an in-person meeting with the U.S. Food & Drug Administration (FDA), scheduled for December 6, 2023. This meeting is a critical step […]
Revolutionizing Recovery: Harnessing Mesenchymal Stem Cells for Spinal Cord Injury Repair
Welcome to an exploration of one of the most promising frontiers in medical science: the use of mesenchymal stem cells (MSCs) in the repair of spinal cord injuries. Spinal cord injuries can be devastating, altering lives in an instant and leaving individuals with significant physical challenges. Traditional therapies have made strides in improving outcomes, yet […]
UP421: Revolutionizing Diabetes Treatment Without Immunosuppression
Uppsala University Hospital and Sana Biotechnology recently announced a groundbreaking development in diabetes treatment. They have received authorization from the Swedish Medical Products Agency for a first-in-human clinical trial of UP421, a novel islet cell therapy for type 1 diabetes. This treatment, developed using Sana’s innovative hypoimmune (HIP) technology, aims to transplant functional islet cells […]
Revolutionizing Stem Cell Research: ACROBiosystems’ DLL4
ACROBiosystems, a pivotal player in the pharmaceutical industry, recently announced the launch of its GMP grade DLL4, a significant advancement in the field of stem cell research and biologics manufacturing. DLL4, or Delta-like Ligand 4, is a recombinant, soluble protein now available in a GMP (Good Manufacturing Practice) compliant form. This launch marks a considerable […]
Transformative Journey with Full Body Stem Cell Makeover® – A Testimonial by Chas Bailes
In a revealing and insightful video by Docere Clinics, Chas Bailes shares his transformative experience with Dr. Harry Adelson’s Full Body Stem Cell Makeover®. This video, published on October 30, 2023, delves into Chas’s initial skepticism, his journey to belief, and the remarkable changes he experienced post-treatment. Discovering Stem Cell Therapy Chas’s path to stem […]
Embryonic Stem Cell Research for Neurodegenerative Diseases
In the realm of medical science, few topics have sparked as much hope and controversy as stem cell therapy. These remarkable cells, with their unique ability to transform into various cell types, are a cornerstone of regenerative medicine. Among them, embryonic stem cells (ESCs) stand out due to their exceptional pluripotency. This article delves into […]
BioCardia Announces FDA Approval for Groundbreaking Heart Failure Treatment
BioCardia, Inc., a prominent player in the development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has recently announced a significant milestone. The U.S. Food and Drug Administration (FDA) has approved the Phase III clinical trial protocol for BioCardia’s CardiAMP autologous cell therapy. This therapy is designed for patients suffering from ischemic heart […]